6467 — TAHO Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- TWD10.61bn
- TWD10.32bn
- TWD8.41m
Annual cashflow statement for TAHO Pharmaceuticals, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -11.4 | -66.3 | -121 | -167 | -214 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 1.94 | 1.92 | -2.34 | -2.08 | 7.36 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | -2.57 | -7.34 | 11.1 | 5.62 | -5.35 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -2.96 | -62.8 | -104 | -157 | -204 |
| Capital Expenditures | -0.408 | -0.829 | -2.89 | -8.82 | -6.31 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -42 | 10 | -46.2 | -180 | 200 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -42.4 | 9.17 | -49 | -189 | 194 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -6.43 | 88.7 | 231 | 440 | 104 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -51.8 | 35.1 | 77.4 | 94.2 | 94.1 |